ATI-045 for Eczema
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ATI-045, a potential drug for moderate-to-severe atopic dermatitis, commonly known as eczema. Participants will receive either ATI-045 or a placebo (a pill with no active medication) to compare results. The trial aims to determine if ATI-045 can improve skin health and reduce symptoms more effectively than the placebo. Ideal candidates have experienced moderate-to-severe eczema for at least six months, have had no major flare-ups recently, and have not found success with previous topical treatments. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important findings.
Will I have to stop taking my current medications?
Yes, you may need to stop certain medications before joining the trial. For example, you must stop using topical antibiotics, certain oral medications, and biologics for eczema for a specific time before the trial starts. It's best to discuss your current medications with the trial team to see if any need to be paused.
Is there any evidence suggesting that ATI-045 is likely to be safe for humans?
Research shows that ATI-045 has been tested in people before. Earlier studies found that most participants tolerated it well, without reporting major side effects. While this does not guarantee the absence of side effects, it suggests that ATI-045 is likely safe based on past trials. This trial aims to provide further insights into its safety for treating eczema.12345
Why do researchers think this study treatment might be promising for eczema?
ATI-045 is unique because it offers a novel approach to treating eczema by potentially targeting the underlying inflammation differently than current options like topical steroids or calcineurin inhibitors. Unlike conventional treatments that primarily focus on managing symptoms, ATI-045 may work by modulating specific immune pathways, offering a more targeted method of reducing inflammation and itchiness associated with eczema. Researchers are excited about ATI-045 because it might provide a more effective and faster-acting solution with potentially fewer side effects, improving the quality of life for those affected by this chronic skin condition.
What evidence suggests that ATI-045 might be an effective treatment for eczema?
Studies have shown that ATI-045, also known as bosakitug, is under investigation as a treatment for moderate-to-severe atopic dermatitis, a chronic skin condition causing itchy, inflamed, and scaly rashes. Early research suggests that ATI-045 might reduce symptoms of this condition. Although results from human trials are not yet available to confirm its effectiveness, researchers are carefully studying the treatment for potential benefits. Participants in this trial will receive either ATI-045 or a placebo, providing more information. Initial findings offer hope for those dealing with this challenging skin disorder.36789
Are You a Good Fit for This Trial?
This trial is for individuals with moderate-to-severe atopic dermatitis, which includes conditions like eczema and various forms of dermatitis. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and may be excluded based on other medical conditions or treatments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ATI-045 or placebo for the treatment of moderate-to-severe atopic dermatitis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ATI-045
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aclaris Therapeutics, Inc.
Lead Sponsor